VI Line
USD
136.92
-0.45 (-0.3%)
NYSE:PKI, PERKINELMER, INC.
Industry: Diagnostics & Research
End of Day: 25 November 2022 GMT-5

Details

Overview Company Info Key Ratios Income Balance Sheet Cash Flow

Could PerkinElmer Be The Next Danaher?

Can a restructuring lead to outperformance?

PerkinElmer, Inc. (PKI) is an American Medical Devices company focused on life sciences and diagnostics. Over the last ten years, the company outperformed the S&P 500 by a wide margin but did not manage to beat the...

more

PerkinElmer: Reiterate Buy, Next Price Objective $155/Share

Investment Summary

From the Portfolio Manager's desk

Following its latest set of numbers, I've sized up our position and reiterated our buy call on PerkinElmer, Inc. (PKI) shares. Here, we run through the synopsis backing the call. Our first price...

more

PerkinElmer's EONIS SCID-SMA assay kit gets FDA approval for use in newborns

Trending News

PerkinElmer, Inc. is a global leader in life sciences. They supply instruments, software, services, and consumables for applications across the research, drug discovery, and clinical diagnostics markets. PerkinElmer's EONIS SCID-SMA assay kit has been granted approval by the US FDA...

more

PerkinElmer receives FDA approval for EONIS assay for spinal muscular atrophy in newborns

  • The US FDA has granted approval to PerkinElmer's (NYSE:PKI) EONIS SCID-SMA assay kit for in vitro diagnostic (IVD) use for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns.
  • The...

more

PerkinElmer, Inc. (PKI) Q3 2022 Earnings Call Transcript

PerkinElmer, Inc. (PKI)

Q3 2022 Earnings Conference Call

November 8, 2022 8:00 AM ET

Company Participants

Steve Willoughby - Senior Vice President, Investor Relations

Prahlad Singh - President and Chief Executive Officer

Max...

more

PerkinElmer, Inc. 2022 Q3 - Results - Earnings Call Presentation

The following slide deck was published by PerkinElmer, Inc. in conjunction with their 2022 Q3 earnings call.

...

- SA Transcripts

https://seekingalpha.com/article/4554684-perkinelmer-inc-2022-q3-results-...

$NYSE:PKI

PerkinElmer reports mixed Q3 earnings, initiates Q4 and updates FY22 pro forma guidance

  • PerkinElmer press release (NYSE:PKI): Q3 Non-GAAP EPS of $1.51 beats by $0.03.
  • Revenue of $1.03B (-12.0% Y/Y) misses by $10M.
  • Pro forma adjusted operating...

more

PerkinElmer falls behind competitors on Monday

Trending News

PerkinElmer, Inc. is a global leader in human and environmental health, providing solutions for a healthier world. On Monday, however, the company's stock lagged behind those of its competitors. This may be due to several factors, including PerkinElmer's recent announcement that it...

more

PerkinElmer to pay quarterly dividend of $0.07 per share

Trending News

PerkinElmer is a leading global provider of diagnostic and research instruments, services, and solutions. The company has a long history of paying dividends, and the latest announcement brings its quarterly dividend payments up to $0.07 per share. The dividend is payable on...

more

PerkinElmer declares $0.07 dividend

  • PerkinElmer (NYSE:PKI) declares $0.07/share quarterly dividend, in line with previous.
  • Payable Feb. 10; for shareholders of record Jan. 20; ex-div Jan. 19.
more

All statements, views or opinions expressed here are the personal views of our users. They do not represent nor should they be construed as representing our statements, views or opinions. For the avoidance of doubt, any such statements, views or opinions are not and shall not be construed as financial advice.

Make Smart Investment Choices